MacroGenics shares are trading higher after the company reported Q3 financial results. Following earnings, Guggenheim upgraded the stock from Neutral to Buy and announced a $12 price target.
Portfolio Pulse from Benzinga Newsdesk
MacroGenics reported Q3 financial results, leading to an upgrade of its stock from Neutral to Buy by Guggenheim, with a price target of $12. This has resulted in MacroGenics shares trading higher.
November 07, 2023 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MacroGenics' Q3 financial results led to an upgrade of its stock by Guggenheim, resulting in higher trading of its shares.
The positive Q3 financial results reported by MacroGenics have led to an upgrade of its stock from Neutral to Buy by Guggenheim. This has increased investor confidence, leading to higher trading of MacroGenics shares. The $12 price target set by Guggenheim also indicates a positive outlook for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100